Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Esophageal Cancer, Radiation Pneumonitis
Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology
Although recent global trends indicate reduced postoperative mortality after esophagectomy, major morbidity, in particular pulmonary, remains high, with considerable health and economic costs.
- Conditions
- Esophageal Cancer, Radiation Pneumonitis, Pulmonary Fibrosis, Respiratory Failure
- Trial name
- NCT03462524
- Testing
- Esophagectomy
- Where
- 2 sites in Ireland
- Volunteers
- 384 people
- Sponsor
- St. James's Hospital, Ireland
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects of pembrolizumab and vorinostat in treating patients with squamous cell head and neck cancer or salivary gland cancer that has come back, has spread to other places in the body…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma
- Trial name
- NCT02538510
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Esophageal Cancer
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
This is a randomized noninferiority multicenter trial. Patients will be stratified according to the participating hospital. Patients will be randomized to one of the treatment arms.
- Trial name
- ASSURE (NCT03306901)
- Testing
- Esophagectomy, 5-fluorouracil, Cisplatin
- Where
- 9 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Samsung Medical Center
Esophageal Squamous Cell Carcinoma
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT assessment to change the following chemoradiotherapy regiment for locally…
- Trial name
- NCT06420908
- Testing
- Adebrelimab+TP/FP+ radiation therapy, Adebrelimab+FP/TP+ radiation therapy
- Sponsor
- Hebei Medical University Fourth Hospital
Head and Neck Squamous Cell Carcinoma
Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)
This is a retrospective study in patients with cancer of the oral cavity, pharynx, and larynx. Imaging exams of these patients will be analyzed with the objective of developing and validating a clinically applicable method for…
- Trial name
- HNCAX01 (NCT04003025)
- Where
- Brazil
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
This phase I clinical trial studies the side effects and best dose of veliparib when given together with paclitaxel and cisplatin and to see how well they work in treating patients with cervical cancer that has spread to other…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Trial name
- NCT01281852
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 25 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the effectiveness of treatment with bevacizumab + cisplatin + cetuximab + IMRT. The doctor wishes to monitor patients for 2 years after the completion of study treatment to determine if…
- Trial name
- NCT00968435
- Testing
- bevacizumab, cisplatin, cetuximab, radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
This phase I trial studies the side effects and best dose of onalespib when given together with intensity-modulated radiation therapy (IMRT) and cisplatin in treating patients with squamous cell carcinoma of the head and neck…
- Conditions
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Trial name
- NCT02381535
- Testing
- Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 2 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
The goal of this clinical research study is to learn which chemotherapy combination may be more effective in treating locally advanced head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT02128906
- Testing
- Cisplatin, IMRT, Docetaxel
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Christopher Wilke
Oral Cancer, VEGFR2 Inhibitor
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
In patients with locally advanced oral squamous cell carcinoma (OSCC), due to the large tumor burden and neck lymph node metastasis, comprehensive treatment is recommended, including surgery, radiotherapy, chemotherapy and…
- Conditions
- Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor, Inductive Therapy
- Trial name
- NCT04393506
- Testing
- Camrelizumab, Apatinib, Radical surgery
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Squamous Cell Carcinoma of Head and Neck
Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer
Post-operative concomitant radiochemotherapy is a treatment that is difficult to achieve for several reasons. First of all, and by definition, these patients have had recent surgery, most often accompanied by several weeks of…
- Trial name
- OPTINECK (NCT04528420)
- Testing
- optimised management
- Where
- 7 sites in France
- Volunteers
- 138 people
- Sponsor
- Centre Henri Becquerel
Head and Neck Squamous Cell Carcinoma
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
The goal of this clinical research study is to learn which chemotherapy combination is more effective in treating locally advanced head and neck squamous cell carcinoma. The side effects of these combinations will also be studied.
- Trial name
- NCT01154920
- Testing
- Paclitaxel, Carboplatin, Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region
Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
To determine if combined [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is performant enough with respect to detecting residual lymph node involvement after chemoradiation in order…
- Trial name
- ECLYPS (NCT01179360)
- Testing
- Integrated FDG PET/CT
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 152 people
- Sponsor
- University Hospital, Antwerp
Oropharyngeal Neoplasms
Human Papillomavirus and Oropharynx Carcinoma
High risk papillomavirus (HR-HPV) have an oncogenic role in Oropharyngeal squamous cell carcinomas (OP-SCC) in at least 25% of the cases and the prevalence is increasing.
- Trial name
- Papillophar (NCT00918710)
- Where
- France
- Volunteers
- 362 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Head and Neck Neoplasms
Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
The primary objectives of the trial is to examine the toxicities and efficacies of afatinib and pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma.
- Trial name
- ALPHA (NCT03695510)
- Testing
- Afatinib Oral Tablet, Pembrolizumab Injection
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- National Taiwan University Hospital
Oral Squamous, Cell Carcinoma
Radio/Pathological Evaluation of Tongue Cancer Infiltration
The aim of the study is to assess the good correlation and prediction of the DOI for the post-operative pathological results and prognosis.
- Trial name
- RaP E ToC (NCT04821128)
- Testing
- Radiologic and pathological review.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Head and Neck Squamous Cell Carcinoma
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
This trial was originally designed and powered to compare biomarker modulation in the neo-adjuvant setting (erlotinib versus erlotinib plus sulindac versus placebo) with clinical response to erlotinib in the adjuvant setting.
- Trial name
- NCT01515137
- Testing
- Erlotinib, Erlotinib plus sulindac
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Pittsburgh
Head and Neck Neoplasms
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
This study will test an investigational study drug called patritumab. It is a 'randomized study' which means participants have an equal chance of being assigned to receive the experimental medication (patritumab) or a substance…
- Trial name
- NCT02633800
- Testing
- Patritumab, Cetuximab, Cisplatin
- Where
- 34 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Daiichi Sankyo
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal…
- Trial name
- NEOCRTEC2501 (NCT07638436)
- Testing
- Adebrelimab Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.